NOTE TO THE FILE
SERIAL NUMBER: 88264600
DATE: 11/12/2019
NAME: kcantone
NOTE:
Searched:
Lexis/Nexis
OneLook
Wikipedia
Acronym Finder Protest evidence reviewed
Other:Checked:
Geographic significance
Surname
Translation
ID with ID/CLASS mailboxChecked list of approved Canadian attorneys and agents
Discussed file with
Attorney/Applicant via:
phone Left message with
email Attorney/ApplicantRequested Law Library search Issued Examiner’s Amendment
for: and entered changes in TRADEUPSPRINT DO NOT PRINT Added design code in TRADEUPS
Description of the mark
Translation statement Re-imaged standard character
drawing
Negative translation statement
Consent of living individual Contacted TM MADRID ID/CLASS
about misclassified definite ID
Changed TRADEUPS to:
From: Schneider, Lindsay <lindsay.schneider@bclplaw.com>
Sent: Tuesday, November 12, 2019 11:53 AM
To: Cantone, Keri <Keri.Cantone@USPTO.GOV>
Cc: Bryan Cave IP Docketing <bcipdocketing@bclplaw.com>
Subject: RE: 88264600 LIGHTSHIP
We are amenable to entry of an Examiner’s Amendment to clarify the Class 42 description, as proposed in your November 11, 2019 message below. Please proceed with entry of an Examiner’s Amendment and approval of the application for publication. Feel free to contact me if any further information is needed.
Respectfully submitted,
/lcs/
LINDSAY COHEN SCHNEIDER
Counsel
BRYAN CAVE LEIGHTON PAISNER LLP - St. Louis, MO USA
lindsay.schneider@bclplaw.com
T: +1 314 259 2481
Docketing: BCIPdocketing@bclplaw.com
From: Cantone, Keri [mailto:Keri.Cantone@USPTO.GOV]
Sent: Monday, November 11, 2019 6:03 PM
To: Schneider, Lindsay
Subject: 88264600 LIGHTSHIP
Ms. Schneider:
The above has come back to me for correction of a portion of the Class 42 identification. The following clarification is required:
Class 42: Conducting clinical trials for others; Medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical and non-clinical trials and studies on pharmaceuticals and medical devices for others; Scientific consulting and research services for others in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Virtual consulting services regarding medical and scientific research in relation to clinical trials only; Design and development of software for use in conducting research in clinical and non-clinical pharmaceutical and medical device and development studies; Software as a service (SAAS) services featuring software for use in a telemedicine platform for use in clinical research; Platform as a service (PAAS) featuring computer software platforms for the purposes of exchanging data between the medical care providers, researchers, and patients; Providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical and non-clinical trials and studies on pharmaceuticals and medical devices; Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; Providing online non-downloadable software for tracking, monitoring, analyzing, generating and reporting patient information and healthcare statistics in clinical and non-clinical pharmaceutical and medical device and development studies
I can be reached via email, or a the number below.
Sincerely,
Keri-Marie Cantone
Trademark Examining Attorney- Law Office 104
United States Patent & Trademark Office
(571) 272-6069
This electronic message is from a law firm. It may contain confidential or privileged information. If you received this transmission in error, please reply to the sender to advise of the error and delete this transmission and any attachments.
We may monitor and record electronic communications in accordance with applicable laws and regulations. Where appropriate we may also share certain information you give us with our other offices (including in other countries) and select third parties. For further information (including details of your privacy rights and how to exercise